Oxford Biomedica’s ESG mission is to deliver life changing gene therapies to patients in an ethical and socially responsible way
Oxford Biomedica is committed to our role as a responsible business and we have a responsible business strategy in place to drive us towards achieving our ESG mission.
Responsible Business Strategy
Our responsible business strategy is focused on five pillars: People; Community; Environment; Innovation and Supply Chain. For more details see the ESG section of the Annual Report (starting page 54).
Oxford Biomedica’s ESG Committee is responsible for the governance and oversight of our ESG commitments.
The ESG Committee is chaired by Nick Page, Chief Operations Officer.
Department heads within the business are responsible for each of the five pillars. Annual ESG objectives are set by the department head responsible for each pillar, in conjunction with the Senior Executive Team.
The ESG Committee is responsible for tracking progress against the objectives and providing regular progress reports to the Senior Executive Team every quarter. Progress updates are also shared in all-company meetings.
Oxford Biomedica’s three values govern the way that Oxford Biomedica does business, how Oxford Biomedica works together and the interactions Oxford Biomedica has with all its stakeholders.
Our values are embedded throughout our people processes – we look for evidence that job candidates share our values upon appointment, and they are an important factor in Oxford Biomedica’s reward principles, whilst our performance management processes ensure values behaviours are measured so they are appropriately recognised and rewarded.
The Group’s values
We always do the right thing. Whatever the situation and consequences, we do what’s right for employees, patients and partners. We make objective decisions and can be trusted to deliver on our commitments.
We succeed together through our passion, commitment and teamwork. Through our actions and behaviours, we create an environment which positively challenges, engages and excites us.
We deliver ground-breaking scientific excellence by nurturing exceptional talent. Together, we continually improve by generating new ideas and creative ways of working to bring about better solutions for patients.
Our commitment to responsible business practices has been recognised with Prime status (as of 25 June 2021).
ISS ESG is the responsible investment arm of ISS and one of the world’s leading rating agencies for sustainable investments. Prime status is awarded to companies with an ESG performance above the sector-specific Prime threshold, which means that they fulfil ambitious absolute performance requirements. For more info: https://www.issgovernance.com/esg/ratings/
The Group’s commitment to responsible business practices were recognised with inclusion in the FTSE4Good index in June 2022. Created by the global index provider FTSE Russell, the FTSE4Good Index Series is designed to measure the performance of companies demonstrating strong Environmental, Social and Governance (ESG) practices. The FTSE4Good indices are used by a wide variety of market participants to create and assess responsible investment funds and other products.